4.4 Article

Methodology and effects of repeated intranasal delivery of DNSP-11 Chock for in awake Rhesus macaques

期刊

JOURNAL OF NEUROSCIENCE METHODS
卷 303, 期 -, 页码 30-40

出版社

ELSEVIER
DOI: 10.1016/j.jneumeth.2018.03.006

关键词

Intranasal; Parkinson's disease; Peptide; Drug delivery

资金

  1. NINDS [NS039787, NS060924]
  2. NCATS [UL1TR000117]
  3. NIA [AG013494, T32-AG000242]
  4. Kentucky INBRE [NCRR 5P20RR016481-12, NIGMS 8P20GM103436-12]
  5. NIH COBRE [NCRR P20RR20171]
  6. Dupree Trust
  7. Estate of Laura C. Miller
  8. PhRMA Foundation
  9. Columbus Foundation

向作者/读者索取更多资源

Background: To determine if the intranasal delivery of neuroactive compounds is a viable, long-term treatment strategy for progressive, chronic neurodegenerative disorders, such as Parkinson's disease (PD), intranasal methodologies in preclinical models comparable to humans are needed. New method: We developed a methodology to evaluate the repeated intranasal delivery of neuroactive compounds on the non-human primate (NHP) brain, without the need for sedation. We evaluated the effects of the neuroactive peptide, DNSP-11 following repeated intranasal delivery and dose-escalation over the course of 10-weeks in Rhesus macaques. This approach allowed us to examine striatal target engagement, safety and tolerability, and brain distribution following a single (125)l-labeled DNSP-11 dose. Results: Our initial data support that repeated intranasal delivery and dose-escalation of DNSP-11 resulted in bilateral, striatal target engagement based on neurochemical changes in dopamine (DA) metabolites-without observable, adverse behavioral effects or weight loss in NHPs. Furthermore, a (125)l-labeled DNSP11 study illustrates diffuse rostral to caudal distribution in the brain including the striatum-our target region of interest. Comparison with existing methods: The results of this study are compared to our experiments in normal and 6-OHDA lesioned rats, where DNSP-11 was repeatedly delivered intranasally using a micropipette with animals under light sedation. Conclusions: The results from this proof-of-concept study support the utility of our repeated intranasal dosing methodology in awake Rhesus macaques, to evaluate the effects of neuroactive compounds on the NHP brain. Additionally, results indicate that DNSP-11 can be safely and effectively delivered intranasally in MPTP-treated NHPs, while engaging the DA system. (C) 2018 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据